In Vitro and In Vivo Antibacterial Activities of DC-159a, a New Fluoroquinolone
| Autor: | Saori Uoyama, Ryo Okumura, Saito Higuchi, Kazuki Hoshino, Kenji Namba, Yuichi Kurosaka, Yoshinori Kashimoto, Yoichi Murakami, Tsuyoshi Otani, Kazue Inoue |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Klebsiella pneumoniae Microbial Sensitivity Tests Biology Gram-Positive Bacteria medicine.disease_cause Garenoxacin Microbiology Mice chemistry.chemical_compound Anti-Infective Agents Moxifloxacin Levofloxacin Drug Resistance Multiple Bacterial Gram-Negative Bacteria Streptococcus pneumoniae medicine Animals Humans Pharmacology (medical) Antibacterial agent Pharmacology Mice Inbred ICR biochemical phenomena metabolism and nutrition Pneumonia Pneumococcal bacterial infections and mycoses biology.organism_classification Ciprofloxacin Disease Models Animal Treatment Outcome Infectious Diseases chemistry Susceptibility Area Under Curve Mice Inbred CBA Female Bacteroides fragilis Fluoroquinolones medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy. 52:65-76 |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.00853-07 |
| Popis: | DC-159a is a new 8-methoxy fluoroquinolone that possesses a broad spectrum of antibacterial activity, with extended activity against gram-positive pathogens, especially streptococci and staphylococci from patients with community-acquired infections. DC-159a showed activity against Streptococcus spp. (MIC 90 , 0.12 μg/ml) and inhibited the growth of 90% of levofloxacin-intermediate and -resistant strains at 1 μg/ml. The MIC 90 s of DC-159a against Staphylococcus spp. were 0.5 μg/ml or less. Against quinolone- and methicillin-resistant Staphylococcus aureus strains, however, the MIC 90 of DC-159a was 8 μg/ml. DC-159a was the most active against Enterococcus spp. (MIC 90 , 4 to 8 μg/ml) and was more active than the marketed fluoroquinolones, such as levofloxacin, ciprofloxacin, and moxifloxacin. The MIC 90 s of DC-159a against Haemophilus influenzae, Moraxella catarrhalis , and Klebsiella pneumoniae were 0.015, 0.06, and 0.25 μg/ml, respectively. The activity of DC-159a against Mycoplasma pneumoniae was eightfold more potent than that of levofloxacin. The MICs of DC-159a against Chlamydophila pneumoniae were comparable to those of moxifloxacin, and DC-159a was more potent than levofloxacin. The MIC 90 s of DC-159a against Peptostreptococcus spp., Clostridium difficile , and Bacteroides fragilis were 0.5, 4, and 2 μg/ml, respectively; and among the quinolones tested it showed the highest level of activity against anaerobic organisms. DC-159a demonstrated rapid bactericidal activity against quinolone-resistant Streptococcus pneumoniae strains both in vitro and in vivo. In vitro, DC-159a showed faster killing than moxifloxacin and garenoxacin. The bactericidal activity of DC-159a in a murine muscle infection model was revealed to be superior to that of moxifloxacin. These activities carried over to the in vivo efficacy in the murine pneumonia model, in which treatment with DC-159a led to bactericidal activity superior to those of the other agents tested. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|